Global Solid Tumor Testing Market Growth Accelerates: Strategic Forecast Predicts $39.95 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Solid Tumor Testing Industry Market Size Be by 2025?
The market encompassing solid tumor testing has experienced robust expansion across the recent past, with projections indicating a rise from $27.96 billion in 2024 to $29.94 billion in 2025, reflecting a 7.1% compound annual growth rate; this upward trajectory during the historical period is largely credited to advancements in personalized or precision medicine, inadequacies in drug delivery targeted specifically to tumors, suboptimal therapeutic outcomes, escalating financial burdens, and the limitations inherent in reductionist strategies when treating cancers chemically.

What's the Long-Term Growth Forecast for the Solid Tumor Testing Market Size Through 2029?
Within the foreseeable future, the market dedicated to testing solid tumors is projected to experience robust expansion, ultimately reaching a valuation of $39.95 billion by the year 2029, propelled by a compound annual growth rate (CAGR) of 7.5%; this upward trajectory during the projection phase is largely fueled by the rising incidence of various cancers, improvements in medical facilities globally, the advent of diagnostic instruments leveraging artificial intelligence and the Internet of Things, and growing support from governmental programs, alongside key market developments such as progress in testing methodologies, the debut of treatment modalities employing nanocarriers, and significant strategic partnerships and next-generation testing apparatus.

View the full report here:
https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

What Are the Key Growth Drivers Fueling the Solid Tumor Testing Market Expansion?
The escalating incidence of cancer is anticipated to be a key factor fueling the expansion of the solid tumor testing market moving ahead. Cancer is fundamentally characterized by the uncontrolled multiplication and dissemination of the body's atypical cells; these malignant cells, termed cancer cells, possess the capacity to infiltrate adjacent tissues and organs, sometimes metastasizing to distant sites via vascular or lymphatic pathways. Approximately 90 percent of cancers diagnosed in adults manifest as solid tumors. Testing methodologies focused on solid tumors are employed for identifying cancer cells circulating in the bloodstream of patients afflicted with these tumors, even prior to their visualization through medical imaging, such as in June 2023 when the Centers for Disease Control and Prevention, America's national public health entity, released data indicating 1,603,844 new cancer diagnoses and 602,347 associated fatalities in the USA during 2020, equating to 403 new cases and 144 deaths per 100,000 individuals. Consequently, the rising occurrence of cancer serves as a primary impetus for the market's growth concerning solid tumor analysis.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

What Are the Key Trends Driving Solid Tumor Testing Market Growth?
A significant current in the solid tumor testing arena involves the growing adoption of cutting-edge liquid biopsy diagnostic tools. Leading firms within this market are directing their efforts toward pioneering these novel liquid biopsy assays as a strategic move to bolster their standing and secure a lead over competitors. As an illustration, in the sixth month of 2020, NeoGenomics Inc., a testing facility based in the United States, introduced its complete collection featuring three distinct liquid biopsy examinations targeted at individuals battling solid tumors. These sophisticated diagnostic methods are engineered to identify malignant cells circulating in the bloodstream of patients afflicted by solid tumors, potentially even prior to visualization via conventional imaging procedures, thereby assisting medical professionals in determining subsequent diagnostic steps or therapeutic interventions. Furthermore, these advancements offer benefits such as being minimally invasive, facilitating earlier disease detection, enabling tailored treatment plans, and possessing FDA authorization. A further benefit these three newly released tests provide is rapid delivery of results, typically within seven days or less, which notably conserves valuable clinician time.

How Is the Solid Tumor Testing Market Segmented?
The solid tumor testingmarket covered in this report is segmented -

1) By Type: Genetic Testing; Conventional Testing
2) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Cervical Cancer
3) By Application: Clinical; Research
4) By End-Users: Hospitals; Pharmaceutical And Biotechnology Companies; Contract Research Organizations; Academic Research Institutions

Subsegments:
1) By Genetic Testing: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Fluorescence In Situ Hybridization (FISH)
2) By Conventional Testing: Histopathology; Cytology; Imaging Techniques

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12658&type=smp

Which Companies Are Leading the Charge in Solid Tumor Testing Market Innovation?
Major companies operating in the solid tumor testing market include Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton dic*kinson And Company (BD), Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Novocure Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Eutropics Pharmaceuticals Inc., Anixa Biosciences Inc., Cellular Biomedicine Group.

Which Regions Are Leading the Global Solid Tumor Testing Market in Revenue?
North America was the largest region in the solid tumor testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12658

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.